PREVIEW ASH 2026 — New Orleans, Dec 12–15: the abstracts hematologists are watching, top voices and trial buzz See the ASH 2026 preview →
KOL Pulse

What's Hot in Hematology/Oncology

Daily DigestTuesday, November 17, 2026

Leading today's oncology KOL conversation on X: FDA approves neladalkib in previously treated ALK+ NSCLC; ivonescimab gets a CRL. The KOL Pulse Daily Digest: what verified physician voices are discussing on X across the major tumor types, ranked by engagement over the last 48 hours.

Lung Cancer@StephenVLiuStephen V Liu, MD · @StephenVLiu

“FDA grants accelerated approval to neladalkib (NVL-655) for advanced ALK positive NSCLC with prior TKI therapy. Based on ALKOVE-1 study - post alectinib RR 49%, more than half of responses ongoing at a year. Favorable tox profile. New best in class? https://t.co/niZ501PNO5”

View post ↗See the ALKOVE-1 approval and KOL reactions →

FDA Approval FDA Grants Accelerated Approval to Neladalkib (Nelkarmi) for Previously Treated ALK+ NSCLC ↗
On November 17, 2026, the FDA granted accelerated approval to neladalkib (Nelkarmi, Nuvalent, Inc.) for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer who previously received one prior ALK tyrosine kinase inhibitor consisting of alectinib, or two or more prior…

FDA Approval FDA Approves Giredestrant (Wilserdly) Plus Everolimus for ESR1-Mutated ER+/HER2- Advanced Breast Cancer ↗
On November 16, 2026, the FDA approved giredestrant (Wilserdly, Genentech) in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, whose disease recurred during or after adjuvant…

🫁Lung Cancer
FDA approves neladalkib in previously treated ALK+ NSCLC; ivonescimab gets a CRL

The FDA granted accelerated approval to neladalkib (Nelkarmi) for advanced ALK-positive NSCLC after one prior ALK TKI consisting of alectinib, or after two or more ALK TKIs and platinum-based chemotherapy, based on the single-arm Phase 1/2 ALKOVE-1 trial (ORR 49% after alectinib). Separately, the FDA issued a complete response letter for ivonescimab plus chemotherapy in EGFR-mutant NSCLC after EGFR TKI therapy (HARMONi), citing the lack of a statistically significant overall survival benefit despite a PFS improvement. KOLs also discussed HERON-Lung01, where the investigational HER3 ADC ruzaltatug rezetecan improved interim PFS versus platinum-pemetrexed (8.3 vs 5.4 months, HR 0.47), with OS still immature.

neladalkibALKOVE-1ivonescimabHARMONiHERON-Lung01SCLC
@StephenVLiu

“FDA grants accelerated approval to neladalkib (NVL-655) for advanced ALK positive NSCLC with prior TKI therapy. Based on ALKOVE-1 study - post alectinib RR 49%, more than half of responses ongoing at a year. Favorable tox profile. New best in class?”

— @StephenVLiu · Neladalkib approval · View post ↗
@Latinamd

“It’s been a weird week. Planes grounded, Outlook down, and now @FDA declines to approve @SMMT_TX ivonescimab for EGFR-mutant lung cancer after osimertinib resistance (HARMONi trial). Despite a meaningful PFS benefit, lack of demonstrated OS benefit was the deciding factor — a challenging standard, particularly when other cancer drugs have been approved with similar PFS/OS discrepancies in this space 🤷🏽‍♀️”

— @Latinamd · Ivonescimab CRL · View post ↗
@LauraAlderMD

“After decades of few advances, progress in SCLC over the past few years has been remarkable.”

— @LauraAlderMD · SCLC progress · View post ↗
📌 Amplified by @KolPulseAI
🎗️Breast Cancer
FDA approves giredestrant plus everolimus for ESR1-mutated HR+/HER2- advanced breast cancer

KOLs welcomed the FDA approval of giredestrant (Wilserdly) plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer that recurred during or after adjuvant endocrine therapy or progressed on at least one endocrine-based regimen in the metastatic setting, the first approval for giredestrant. In evERA, giredestrant plus everolimus versus standard-of-care endocrine therapy plus everolimus improved PFS in the ESR1-mutated population (10 vs 5.5 months) and ORR (27% vs 14%); patients without a detectable ESR1 mutation are not covered by the approval. Physicians flagged everolimus-related stomatitis prophylaxis. Separately, commenting on treatment-sequencing surveys, Harold Burstein argued against defining a fixed sequence in advanced ER+ breast cancer without comparative data.

giredestrantevERAoral SERDESR1everolimus
@antgiorda

“Great news for patients with HR+/HER2- metastatic breast cancer! How many times have we had to update this treatment algorithm in 2026? Oral SERDs are increasingly an option for patients with ESR1-mutated disease.”

— @antgiorda · evERA approval · View post ↗
📌 Amplified by @KolPulseAI
@PTarantinoMD

“We have a new FDA-approved oral SERD combo for HR+ mBC! In evERA, led by @elmayermd, giredestrant (vs SoC ET) + everolimus nearly doubled PFS (10 vs 5.5 mo) and ORR (27% vs 14%) in patients with ESR1 mutations. Another important option for our patients!”

— @PTarantinoMD · evERA approval · View post ↗
📌 Amplified by @KolPulseAI
@dr_yakupergun

“🚨 Great news! FDA approves giredestrant + everolimus for ESR1-mutated ER+/HER2− aBC Watch out for everolimus-related stomatitis! Don’t forget dexamethasone mouthwash. Perhaps 7.5 mg of everolimus would be a better option, as in ELEVATE and ADALE...”

— @dr_yakupergun · Everolimus stomatitis · View post ↗
@DrHBurstein

“These kinds of surveys are based on a false assumption that there is a specific optimal sequence of treatment in advanced, ER+ breast cancer. The better metaphor is of a buffet table. You are going to have the chance to try everything, and the sequence of treatment is dictated by what appeals at the moment based on clinical cancer burden, prior therapy, biomarkers (to some degree), and treatment logistics/safety/tolerability profile. Every clinician knows this. We should resist the KOL- and pharma-driven desire to specify a treatment plan in the absence of any data, absence of studies comparing one in-class drug versus another, absence of studies designed to test real sequences of treatment vs generating FDA approvals.”

— @DrHBurstein · Treatment sequencing · View post ↗
🔵GI Cancers
Daraxonrasib wins EU approval in previously treated metastatic pancreatic cancer

The European Commission granted marketing authorization to daraxonrasib (Rasonque), an oral RAS(ON) multi-selective inhibitor, as monotherapy for adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy, with or without an identified RAS mutation, based on the Phase 3 RASolute 302 trial (median OS 13.2 vs 6.7 months, HR 0.40). In the US, daraxonrasib has been FDA-approved since August 2026 for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. KOLs also shared the KEYNOTE-585 FLOT-cohort analysis in gastric and GEJ cancer, and a HEP Journal report in which Y90 radioembolization downstaged 25% of HCC patients with tumoral portal vein thrombosis to transplant eligibility.

daraxonrasibRASolute 302pancreatic cancerKEYNOTE-585HCC
@niklas_kluemper

“Targeting the once “undruggable” RAS is becoming clinical reality.”

— @niklas_kluemper · Daraxonrasib EU approval · View post ↗
@niklas_kluemper

“Could this be the EV+pembro moment for PDAC? 🔥 Different disease, different mechanism—but a similarly profound shift in treatment.”

— @niklas_kluemper · Daraxonrasib EU approval · View post ↗
@ArndtVogel

“👉SIRT downstaged 25% of PVTT pts to transplant eligibility”

— @ArndtVogel · Y90 downstaging in HCC · View post ↗
Free Access · KOL Pulse Intelligence

Track oncology’s top KOLs in your specialty

Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:

  • ✓Enhanced KOL profiles
  • ✓Pharma influence & potential advisory-board patterns
  • ✓2025 Open Payments financial analysis
  • ✓Social-media sentiment & trend signals
Get free access — pick your specialty
Choose the tumor types you follow. No cost, unsubscribe anytime.
🔷GU Cancers
After EV plus pembrolizumab: KOLs weigh MIBC regimens and next steps in kidney cancer

At #UromigosLive, a panel compared the two FDA-approved perioperative enfortumab vedotin regimens in muscle-invasive bladder cancer (with pembrolizumab or with durvalumab), concluding both are reasonable; Tom Powles suggested that picking one and using it well may matter more than the choice itself. In kidney cancer, KOLs noted that adding belzutifan or quavonlimab to pembrolizumab plus lenvatinib in first-line mRCC did not beat the doublet (LITESPARK-012), while belzutifan plus lenvatinib improved PFS over cabozantinib after a PD-1/PD-L1 inhibitor (LITESPARK-011). An IMmotion010 analysis found that RCC recurring after adjuvant atezolizumab had lower MHC-I expression than recurrence after placebo, a hypothesis-generating argument for a VEGF-based next line. MSK outlined trials of new targets, payloads, T-cell engagers and radioligands for disease progressing after EV plus pembrolizumab.

enfortumab vedotinMIBCLITESPARK-012LITESPARK-011belzutifanUromigosLive
@neerajaiims

“Adding belzutifan or quavonlimab (CTLA-4) to pembro+len in 1L mRCC did not beat pembro+len alone👇VEGF-TKI/IO based triplets keep falling short👉The doublet bar is high.”

— @neerajaiims · LITESPARK-012 · View post ↗
📌 Amplified by @KolPulseAI
@katy_beckermann

“RCC that recurs after adjuvant atezolizumab has different RNA signatures than RCC after placebo. IMmotion010: 🧬 Placebo arm: more B cell and macrophage signatures 🧬 Atezolizumab arm: lower MHC-I, which presents tumor antigen to T cells 🔍 80 of 754 had recurrence tissue Lower MHC-I argues for a VEGF-based next line over more IO. Still hypothesis-generating. 🧪 Testing a HIF-2α inhibitor + VEGF TKI after IO: PEAK-1, LITESPARK-033, LITESPARK-034”

— @katy_beckermann · IMmotion010 recurrence biology · View post ↗
📌 Amplified by @KolPulseAI
@Dr_Aggen

“Trials are critical for defining what comes after EV + pembrolizumab (EV/P) in advanced bladder cancer?”

— @Dr_Aggen · After EV/P · View post ↗
📌 Amplified by @KolPulseAI
🟣Multiple Myeloma & Plasma Cell Disorders
Cevostamab after CAR-T at IMS26 and BCMA bispecifics in AL amyloidosis lead myeloma talk

At #IMS26, the single-arm STEM trial reported cevostamab consolidation starting 10 to 12 weeks after commercial cilta-cel or ide-cel in 27 patients, with 24 of 27 in sCR at 1 year post CAR-T; Dr. Ankit Kansagra highlighted the cost in stacked cytopenias (neutropenia 78%, 48% grade 3/4) and noted that a multicenter randomized phase 2 is in development to separate cevostamab's contribution from CAR-T alone. At #ISA2026, BCMA bispecifics in relapsed/refractory AL amyloidosis showed fast, deep responses, with infection the key risk and IVIG prophylaxis emphasized. Etentamig, an investigational BCMA bispecific with less frequent dosing, was reported as submitted to the FDA as a BLA, and KOLs began sharing their top myeloma abstracts ahead of ASH 2026.

cevostamabSTEM trialCAR-TAL amyloidosisteclistamabetentamigASH 2026
@kansagraMD

“If we can pick out the pts heading for early relapse and consolidate only them, this gets a lot easier to justify.”

— @kansagraMD · STEM trial · View post ↗
📌 Amplified by @KolPulseAI
@morenodegusmao

“BCMA bispecifics in R/R AL at #ISA2026: elranatamab (phase I/II, n=11) and teclistamab (real-world, n=52). Fast, deep responses, no ICANS. Infection is the key risk: sepsis deaths 3/42 with IVIG vs 5/8 without. Very different populations (Mayo IIIB 0% vs 25%).”

— @morenodegusmao · Bispecifics in AL amyloidosis · View post ↗
📌 Amplified by @KolPulseAI
@HadidiSamer

“A BCMA BsAb with less frequent dosing resulted in high efficacy with less side effects, now hope we can get this as subcutaneous in the future since it is currently IV”

— @HadidiSamer · Etentamig · View post ↗
📌 Amplified by @KolPulseAI
🩸Leukemia & Lymphoma
Microbiome diversity after transplant, TP53 in higher-risk MDS, and the 2L DLBCL control-arm question

Primary results of BMT CTN 1801 in Nature Medicine found that microbiome diversity at engraftment did not predict 1-year non-relapse mortality, although lower diversity was associated with worse overall survival and was lower with post-transplant cyclophosphamide. KOLs also shared a VALIDATE-database analysis of TP53 mutations in higher-risk MDS treated with hypomethylating agents, a Nature paper asking whether AML could begin 50 years before diagnosis, and a discussion of GLP-1 receptor agonist use and blood cancer risk. Dr. David Russler-Germain asked what the most realistic new control arm is for second-line DLBCL randomized trials, for both CAR-T-eligible and CAR-T-ineligible patients.

BMT CTN 1801microbiomeMDSTP53DLBCLGLP-1
@MediHumdani

“Primary results of @BMTCTN 1801 in @NatureMedicine 1. Mirobiome diversity (MiDv) at engraftment not predictive of NRM @1yr 2. Lower MiDv = ⬇️OS 3. MiDv lower w/PTcy 4. GvHD prophy likely exert effects on both the Mi and immune compartments”

— @MediHumdani · BMT CTN 1801 · View post ↗
@dgermain21

“Honest Q that I don’t know answer to: What is the best / most realistic new control arm for 2L DLBCL RCTs? Give me CART eligible and CART ineligible options :) #nomorergemox”

— @dgermain21 · 2L DLBCL control arm · View post ↗
Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Quotes are verbatim from physicians' public posts on X and cross-checked by an automated audit. Last updated November 17, 2026.